CureVac Secures Key Patent Victory in Litigation with BioNTech

The latest update is out from CureVac ( (CVAC) ).

On May 15, 2025, CureVac announced a favorable decision from the European Patent Office (EPO) in its ongoing patent litigation with BioNTech SE. The EPO upheld the validity of CureVac’s patent EP 4 023 755 B1, subject to amendments, marking a positive development in the dispute involving six intellectual property rights. This decision strengthens CureVac’s position in the biotech industry, particularly in the mRNA technology domain, as it prepares for a hearing on July 1, 2025, regarding patent infringement claims that could lead to damage assessments if ruled in CureVac’s favor.

The most recent analyst rating on (CVAC) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on CureVac stock, see the CVAC Stock Forecast page.

Spark’s Take on CVAC Stock

According to Spark, TipRanks’ AI Analyst, CVAC is a Outperform.

CureVac’s overall score reflects a company with substantial financial improvements, attractive valuation, and strategic partnerships, particularly with GSK. The strong cash position and advancements in oncology are positive indicators. However, past volatility in financial performance and operational challenges like restructuring costs remain concerns. The technical indicators suggest moderate positive momentum, enhancing the stock’s attractiveness for investors.

To see Spark’s full report on CVAC stock, click here.

More about CureVac

CureVac N.V. is a pioneering multinational biotech company founded in 2000, specializing in messenger RNA (mRNA) technology for human medicine. The company has developed key technologies essential for mRNA vaccines against COVID-19 and is expanding into new therapeutic areas. CureVac is focused on designing and developing cancer vaccines, prophylactic vaccines, and treatments that enable the body to produce therapeutic proteins. Headquartered in Tübingen, Germany, CureVac operates in the Netherlands, Belgium, Switzerland, and the U.S.

Average Trading Volume: 624,285

Technical Sentiment Signal: Hold

Current Market Cap: $764.4M

Learn more about CVAC stock on TipRanks’ Stock Analysis page.